Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Aurobindo Pharma Business Update

Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.

Source

NSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Aurobindo Pharma Ltd: key numbers

Share price
₹1,644.80
Market cap
₹95,530 Cr
Revenue (annual)
₹33,653 Cr
Net profit (annual)
₹3,505 Cr
P/E (TTM)
24.2×Sector 46.5×
Promoter holding
51.88%+0.00% QoQ
FII holding
17.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Aurobindo Pharma Ltd

All →
21:24 IST NSE
Product Launch

Aurobindo Pharma Product Launch

Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.

Other business update announcements

All →